Solventum vs Eli Lilly

Side-by-side comparison of AI visibility scores, market position, and capabilities

Eli Lilly leads in AI visibility (81 vs 76)
Solventum logo

Solventum

LeaderHealthcare Tech

Medical Technology

Solventum (SOLV) reported ~$8.2B revenue in FY2024. Medical technology company spun off from 3M in 2024, providing wound care, oral care, healthcare IT, and purification products. HQ: Maplewood, MN.

AI VisibilityBeta
Overall Score
B76
Category Rank
#72 of 596
AI Consensus
81%
Trend
stable
Per Platform
ChatGPT
77
Perplexity
78
Gemini
71

About

Solventum Corporation is a global medical technology company spun off from 3M Company in April 2024, combining 3M's Health Care segment into an independent publicly traded entity. The company operates four business segments: MedSurg (wound management, surgical solutions), Dental Solutions (3M/Solventum brand dental products), Health Information Systems (clinical documentation and coding software), and Purification & Filtration (membrane filtration for pharmaceuticals and food/beverage). The spinoff created a focused MedTech company with $8+ billion in revenue and operations in over 70 countries.

Full profile
Eli Lilly logo

Eli Lilly

LeaderHealthcare

General

Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.

AI VisibilityBeta
Overall Score
A81
Category Rank
#17 of 596
AI Consensus
71%
Trend
stable
Per Platform
ChatGPT
80
Perplexity
75
Gemini
77

About

Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.

Full profile

AI Visibility Head-to-Head

76
Overall Score
81
#72
Category Rank
#17
81
AI Consensus
71
stable
Trend
stable
77
ChatGPT
80
78
Perplexity
75
71
Gemini
77
73
Claude
86
72
Grok
85

Key Details

Category
Medical Technology
General
Tier
Leader
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Solventum
Medical Technology

Integrations

Only Solventum
Solventum is classified as company. Eli Lilly is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.